Chuangsheng Group announced that it will announce the phase I updated clinical data of its pH-dependent PD-L1 antibody MSB2311 at the ASCO conference in 2021

Chuangsheng Group, a clinical stage international biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical research and development, clinical and process development and production, today announced that it will pass the abstract online at the 57th American Society of Clinical Oncology (ASCO) The method of publication announced the update of the safety and efficacy data of the phase I clinical study of its pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China
.

Published online

title:

Updated safety and efficacy of MSB2311 (an Anti-Programmed Death-Ligand 1 Antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase I study.

Update on the safety and efficacy data of the Phase I clinical study of pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China

Abstract Number: e14547

First author:

Shen Lin, Doctor of Medicine (Peking University Cancer Hospital)

About MSB2311:

MSB2311 is a humanized antibody that binds to PD-L1 in a pH-dependent manner
.